Climacteric symptoms after oral and percutaneous hormone replacement therapy.
One hundred and ten (110) healthy early post-menopausal women with mild subjective vasomotor symptoms (mean Kupperman index score 11) participated in a long-term, double-blind, placebo-controlled therapeutic trial. The effects of 2 hormone regimens were evaluated. Group I received percutaneous oestrogen therapy for 2 yr, opposed by oral micronized progesterone (200 mg) during the second year, while Group II received oral 17 beta-oestradiol valerate together with cyproterone acetate (CPA). The serum oestrogen concentrations differed markedly in the 2 treatment groups. In Group I the serum/oestrone/oestradiol ratio was 1 (comparable to the pre-menopausal value), but in group II the ratio was greater than 5. Despite the difference in the serum oestradiol and oestrone concentrations, the mean symptom scores were rapidly and similarly reduced in both treatment groups (P less than 0.001). They remained low throughout the study and were not significantly different from pre-menopausal values.
D000279:Administration, Cutaneous; D000284:Administration, Oral; D002979:Climacteric / Q000097:blood / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003534:Cyproterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017373:Cyproterone Acetate; D004311:Double-Blind Method; D004958:Estradiol / Q000008:administration & dosage / Q000097:blood; D004970:Estrone / Q000097:blood; D005260:Female; D012739:Gonadal Steroid Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D011374:Progesterone / Q000008:administration & dosage
D012739:Gonadal Steroid Hormones; D004970:Estrone; D011374:Progesterone; D017373:Cyproterone Acetate; D004958:Estradiol; D003534:Cyproterone